6533b853fe1ef96bd12ac3f8
RESEARCH PRODUCT
LAAE-14, a new anti-inflammatory drug, increases the survival ofCandida albicans-inoculated mice
Mario AlvesEva VillamónEsther Del OlmoMiguel PayáM. Luisa GilRut LucasDaniel Gozalbosubject
Microbiology (medical)Ratónmedicine.drug_classmedicine.medical_treatmentImmunologyHyphaeMicrobiologyDinoprostoneAnti-inflammatoryMicrobiologyGlutaratesMiceIn vivoCandida albicansmedicineAnimalsImmunology and AllergyProstaglandin E2Candida albicansCells CulturedMice Inbred ICRbiologyAnti-Inflammatory Agents Non-SteroidalCandidiasisGeneral Medicinebiology.organism_classificationSurvival AnalysisCorpus albicansIn vitroDisease Models AnimalInfectious DiseasesMacrophages PeritonealProstaglandin Emedicine.drugdescription
LAAE-14, a lipidic acid-amido ether derivative, has been recently described as a new anti-inflammatory drug. We have studied the effect of treatment with this compound on the susceptibility of mice to in vivo experimental Candida albicans infection. ICR mice orally treated with LAAE-14 (25 mg kg(-1)) and experimentally intravenously infected showed a significantly increased survival as compared to control mice. In vitro, the compound did not inhibit the growth of C. albicans yeast cells or the yeast-to-hyphal transition. The in vitro production of prostaglandin E2 by peritoneal macrophages in response to the yeasts and hyphae of C. albicans was significantly decreased upon treatment with LAAE-14, in a dose-dependent manner. Thus, reduced prostaglandin production during fungal infection could be an important factor in controlling fungal colonisation and infection.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2003-09-24 | FEMS Immunology & Medical Microbiology |